CGRYX
Price
$33.95
Change
-$0.01 (-0.03%)
Updated
Aug 6 closing price
Net Assets
746.14M
RMFCX
Price
$59.40
Change
+$0.01 (+0.02%)
Updated
Aug 6 closing price
Net Assets
108.54B
Interact to see
Advertisement

CGRYX vs RMFCX

Header iconCGRYX vs RMFCX Comparison
Open Charts CGRYX vs RMFCXBanner chart's image
Invesco Comstock Select Y
Price$33.95
Change-$0.01 (-0.03%)
VolumeN/A
Net Assets746.14M
American Funds American Mutual R3
Price$59.40
Change+$0.01 (+0.02%)
VolumeN/A
Net Assets108.54B
CGRYX vs RMFCX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
CGRYX vs. RMFCX commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGRYX is a Hold and RMFCX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 109B vs. CGRYX (746M). CGRYX pays higher dividends than RMFCX: CGRYX (1.75) vs RMFCX (1.26). CGRYX was incepted earlier than RMFCX: CGRYX (29 years) vs RMFCX (23 years). RMFCX (0.91) is less costly to investors than CGRYX (0.69). CGRYX is a more actively managed with annual turnover of: 70.00 vs. RMFCX (31.00). RMFCX has a lower initial minimum investment than CGRYX: RMFCX (250) vs CGRYX (1000). RMFCX annual gain was more profitable for investors over the last year : 10.70 vs. CGRYX (-1.66). RMFCX (54.40) and CGRYX (53.23) have equivalent 5 years return.
CGRYXRMFCXCGRYX / RMFCX
Total Expense Ratio0.680.9175%
Annual Report Gross Expense Ratio0.690.9176%
Fund Existence29 years23 years-
Gain YTD5.2379.48655%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets746M109B1%
Annual Yield % from dividends1.751.26139%
Returns for 1 year-1.6610.70-16%
Returns for 3 years3.9425.7015%
Returns for 5 years53.2354.4098%
Returns for 10 years20.0678.6925%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EXPE185.143.30
+1.81%
Expedia Group
ABUS3.470.06
+1.76%
Arbutus Biopharma Corp
LDWY5.180.08
+1.62%
Lendway
KYMR41.35-1.62
-3.77%
Kymera Therapeutics
AIXI1.63-0.07
-4.12%
XIAO-I Corporation